...
首页> 外文期刊>Clinical transplantation. >Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction
【24h】

Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction

机译:延迟煅烧酶抑制剂在肝脏移植受者接受Basiliximab诱导的肝癌中的引入和肾果菌

获取原文
获取原文并翻译 | 示例
           

摘要

Background To investigate the impact of delayed calcineurin inhibitor (CNI) initiation in liver transplant recipients (LTR) with peri-operative renal insufficiency receiving basiliximab induction, we compared renal outcomes of LTR stratified by the degree of achieved post-operative renal recovery (RR) prior to CNI initiation. Methods All adult LTR transplanted between 01/2007 and 12/2015 who received basiliximab were included. Patients who received multi-organ transplantations, were repeat transplant recipients, or expired prior to post-operative day (POD) 90 were excluded. The primary outcome of our retrospective analysis was renal function at POD 90. Results A total of 210 patients were included in our final analysis. Most patients were Caucasian males undergoing liver transplantation for liver disease secondary to hepatitis C virus. Baseline characteristics were similar among the evaluable population. Estimated GFR was significantly higher among patients with the greatest degree of post-operative renal recovery at POD 90; however, this difference did not persist at POD 180. There was no significant difference in incidence or severity of biopsy-proven acute rejection (BPAR) at any measured time point. Conclusions Delayed CNI initiation following liver transplantation in patients with post-operative renal insufficiency who receive basiliximab induction does not adversely affect the incidence of BPAR or long-term renal outcomes.
机译:背景技术探讨延迟钙素抑制剂(CNI)引发在肝脏移植受者(LTR)中的影响,随着Peri-iling肾功能不全接受Basiliximab诱导,我们将LTR分层的肾脏结果与术后肾复苏(RR)进行了比较分层在CNI开始之前。方法包括所有接受Basiliximab的01/2007和12/2015之间移植的所有成人LTR。接受多器官移植的患者是重复移植受者,或在术后日(POD)之前过期(POD)被排除在外。我们回顾性分析的主要结果是POD 90的肾功能。结果总共包括210名患者的最终分析。大多数患者是高加索男性接受肝脏疾病的肝脏移植,其继发于丙型肝炎病毒。基线特征在评价人群中相似。在POD 90术后术后肾脏复苏程度最大程度的患者中估计的GFR显着高;然而,这种差异在POD 180下不存在。在任何测量的时间点处,活组织检查证明急性排斥(BPAR)的发病率或严重程度没有显着差异。结论肝移植后患者患者延迟CNI启动,患有Basiliximab诱导的术后肾功能不全不会对BPAR或长期肾果菌的发生率产生不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号